Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 5% - Should You Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) traded up 5% on Tuesday . The stock traded as high as $26.80 and last traded at $26.71. 62,092 shares traded hands during trading, a decline of 68% from the average session volume of 196,014 shares. The stock had previously closed at $25.43.

Analysts Set New Price Targets

DNTH has been the topic of several research reports. Wedbush lowered their target price on Dianthus Therapeutics from $38.00 to $36.00 and set an "outperform" rating on the stock in a research note on Friday, August 9th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a research note on Thursday, September 26th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a research report on Friday, July 26th. They issued an "outperform" rating and a $58.00 price objective for the company. Cantor Fitzgerald assumed coverage on shares of Dianthus Therapeutics in a report on Thursday, June 27th. They set an "overweight" rating on the stock. Finally, Baird R W raised shares of Dianthus Therapeutics to a "strong-buy" rating in a report on Friday, July 26th. Nine research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average price target of $45.13.

Dianthus Therapeutics Trading Up 8.3 %

The company has a market cap of $808.27 million, a P/E ratio of -4.72 and a beta of 1.85. The company's fifty day moving average is $27.70 and its 200 day moving average is $26.07.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by ($0.01). Dianthus Therapeutics had a negative net margin of 1,376.42% and a negative return on equity of 21.03%. The business had revenue of $1.86 million for the quarter, compared to analysts' expectations of $0.63 million. Analysts anticipate that Dianthus Therapeutics, Inc. will post -2.28 EPS for the current year.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of hedge funds have recently modified their holdings of DNTH. SG Americas Securities LLC grew its stake in shares of Dianthus Therapeutics by 104.0% in the third quarter. SG Americas Securities LLC now owns 8,839 shares of the company's stock worth $242,000 after purchasing an additional 4,506 shares during the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Dianthus Therapeutics in the 2nd quarter worth approximately $236,000. Point72 Asia Singapore Pte. Ltd. grew its position in shares of Dianthus Therapeutics by 281.9% in the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 39,504 shares of the company's stock worth $1,022,000 after buying an additional 29,159 shares during the last quarter. Point72 DIFC Ltd purchased a new position in shares of Dianthus Therapeutics during the second quarter valued at approximately $334,000. Finally, Great Point Partners LLC raised its holdings in shares of Dianthus Therapeutics by 21.3% during the second quarter. Great Point Partners LLC now owns 757,929 shares of the company's stock valued at $19,615,000 after acquiring an additional 132,929 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.